Clinical trials: Elevated Inflammatory Markers
Obesity
Effects of Two Hypocaloric Diets on Weight Loss
The investigators evaluated whether an energy-restricted protein diet with low glycaemic index carbohydrates and soluble fibers (LC-P-LGI) would be more effective than a conventional diet (LC-CONV) on weight-loss and related…
- Trial name
- NCT01312740
- Testing
- LC-P-LGI diet, LC-CONV
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Ceprodi S.A. Kot
Coronary Artery Disease
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable…
- Trial name
- NCT07830719
- Testing
- YMI024
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Polyphenolic Compounds and Metabolism
Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.
The proposed study aims to investigate that consumption of grape seed extract (GSE) would improve antioxidant status and impaired insulin action following consumption of a pro-oxidative high carbohydrate, high fat (HCHF) meal in…
- Trial name
- GSE2 (NCT01995643)
- Testing
- Active Capsule
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline